Postesophagectomy chylothorax: incidence, risk factors, and outcomes
- PMID: 22245587
- PMCID: PMC3430511
- DOI: 10.1016/j.athoracsur.2011.10.060
Postesophagectomy chylothorax: incidence, risk factors, and outcomes
Abstract
Background: Chylothorax is a rare but potentially lethal complication of esophagectomy. This study evaluated the rate of postesophagectomy chylothorax, identified associated risk factors, and compared postoperative outcomes in patients with and without chylothorax.
Methods: We reviewed 892 consecutive patients who underwent esophagectomy (1997 to 2008). Preoperative, operative, and postoperative details, including adverse outcomes and mortality, were analyzed.
Results: Postesophagectomy chylothorax occurred in 34 patients (3.8%). Chylothorax was significantly associated with 30-day major complications (85% vs 46%; p<0.001), including an increased likelihood of sepsis (p=0.001), pneumonia (p=0.009), reintubation (p=0.002) or reoperation (p<0.001), and death (17.7% vs 3.9%, p<0.001). Median length of stay was 17 vs 8 days (p=0.005). Median time to chylothorax diagnosis was 5 days. Thoracic duct ligation was performed in 21 (62%) at a median 13 days after esophagectomy. Two patients required repeat duct ligation for persistent chylothorax. Squamous cell cancer histology (9 of 34; 26%) was an independent predictor of postoperative chylothorax (odds ratio, 4.18; 95% confidence interval, 1.39 to 12.6). Odds of chylothorax were 36 times greater with average daily chest tube output exceeding 400 mL in the first 6 postoperative days (odds ratio, 35.9; 95% confidence interval, 8.2 to 157.8).
Conclusions: Postoperative chylothorax is associated with significant postoperative morbidity and mortality. Patients with squamous cell cancer may be at increased risk. In addition, average daily chest tube output exceeding 400 mL in the early postoperative period should prompt fluid analysis for chylothorax to facilitate early diagnosis and consideration of thoracic duct ligation.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Figures
Comment in
-
Postesophagectomy chylothorax and esophageal squamous cell cancer: missing link?Ann Thorac Surg. 2013 Jan;95(1):386-7. doi: 10.1016/j.athoracsur.2012.06.037. Epub 2012 Dec 25. Ann Thorac Surg. 2013. PMID: 23272881 No abstract available.
-
Prophylaxis of chylothorax after esophagectomy.Ann Thorac Surg. 2013 Jan;95(1):387. doi: 10.1016/j.athoracsur.2012.06.038. Epub 2012 Dec 25. Ann Thorac Surg. 2013. PMID: 23272882 No abstract available.
References
-
- Cagol M, Ruol A, Castoro C, Alfieri R, Michieletto S, Ancona E. Prophylactic thoracic duct mass ligation prevents chylothorax after transthoracic esophagectomy for cancer. World journal of surgery. 2009;33:1684–1686. - PubMed
-
- Cerfolio RJ, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Postoperative chylothorax. J Thorac Cardiovasc Surg. 1996;112:1361–1365. discussion 1365-1366. - PubMed
-
- Cope C. Diagnosis and treatment of postoperative chyle leakage via percutaneous transabdominal catheterization of the cisterna chyli: a preliminary study. J Vasc Interv Radiol. 1998;9:727–734. - PubMed
-
- Cope C, Salem R, Kaiser LR. Management of chylothorax by percutaneous catheterization and embolization of the thoracic duct: prospective trial. J Vasc Interv Radiol. 1999;10:1248–1254. - PubMed
-
- Crandall LJ, Barker S, Graham D. A study of the lymph from a patient with thoracic duct fistula. Gastroenterology. 1943;1:1040–1042.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
